Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 12 of 12 for “"IGHV"”.

  1. Evaluation of TP53 and IGHV clinical molecular prognostic testing for patients with Chronic Lymphocytic Leukaemia at Tygerberg Hospital

    … the immunoglobulin heavy chain variable region (IGHV) gene have emerged as critical molecular prognostic biomarkers with significant therapeutic implications for risk stratification and treatment selection. This study aimed to optimise, validate, and verify polymerase chain reaction (PCR)-based …

    stellenbosch Repository record for Evaluation of TP53 and IGHV clinical molecular prognostic testing for patients with Chronic Lymphocytic Leukaemia at Tygerberg Hospital (opens in a new tab)

  2. Ldoc1, A Novel Biomarker of Prognosis In Chronic Lymphocytic Leukemia

    … the immunoglobulin heavy chain variable region (IGHV) genes. Patients whose CLL cells have unmutated IGHV genes have a median survival of 8 years; those with mutated IGHV genes have a median survival of 25 years. To identify new prognostic biomarkers and molecular targets for therapy in untreated …

    uthsc Repository record for Ldoc1, A Novel Biomarker of Prognosis In Chronic Lymphocytic Leukemia (opens in a new tab)

  3. Characterisation of genetic complexity in chronic lymphocytic leukaemia

    … of the immunoglobulin variable heavy-chain (IgHV) in 497 pre-treatment CLL patients found IgHV subclones in 18.5%, far higher than previously reported. SNP array analysis in 411 CLL patients refined the minimally overlapping regions (MOR) on del(6q) to the ATG5 and PRDM1 genes. Further …

    oxford-brookes Repository record for Characterisation of genetic complexity in chronic lymphocytic leukaemia (opens in a new tab)

  4. Array based genetic profiling of chronic lymphocytic leukemia

    … unmutated immunoglobulin heavy chain variable (IGHV) genes and treated patients with mutated IGHV genes often gained novel aberrations. In paper III, high-density screening revealed a different spectrum of genomic aberrations in CLL patients with ‘stereotyped’ IGHV3-21 (poor-prognostic) versus …

    lund Repository record for Array based genetic profiling of chronic lymphocytic leukemia (opens in a new tab)

  5. Functional role of ZAP70 in Chronic Lymphocytic Leukaemia

    … There are 2 main subtypes of CLL based on the IgHV status: Un-mutated CLL (UM-CLL) and Mutated CLL (M-CLL). M-CLL leads to good prognosis whereas UM-CLL is the more aggressive form of the disease that could lead to Richter syndrome. Prognostics markers for CLL are the IgHV mutational status, …

    cambridge Repository record for Functional role of ZAP70 in Chronic Lymphocytic Leukaemia (opens in a new tab)

  6. Novel approaches to assess cellular interactions and their role in the pathology and treatment of lymphoproliferative disorders

    … 1 (NOTCH1) genes, which are all more frequent in IGHV-unmutated disease. This work describes the development of techniques to characterise and quantify morphological responses to inhibitors, aiming to produce a quantitative description of cytoskeletal changes relating to specific signalling …

    plymouth Repository record for Novel approaches to assess cellular interactions and their role in the pathology and treatment of lymphoproliferative disorders (opens in a new tab)

  7. A novel genomics and bioinformatics approach to assess immunoglobulin and T cell receptor rearrangements and somatic hypermutation in lymphoproliferative disorders

    … was found to significantly correlate with SSeq IGHV%.<br/><br/>Novel bioinformatic analysis of IGHJ-E and introduction of a stringent 99.8% mutational threshold in tested LPD cohorts found between 88.16-97.44% concordance (90.3% in all 175 samples) with SSeq SHM status. Poor SHM stratification …

    qu-belfast Repository record for A novel genomics and bioinformatics approach to assess immunoglobulin and T cell receptor rearrangements and somatic hypermutation in lymphoproliferative disorders (opens in a new tab)

  8. Molecular Insights of Primary Thyroid B-cell Lymphomas by Somatic Genetic and Immunogenetic Profiling

    … found significant overrepresentation of several *IGHV* genes including *IGHV1-46*, *IGHV3-23*, *IGHV3-49*, *IGHV4-61* and *IGHV4-34* in thyroid lymphomas. A high proportion (70%) of *IGHV3-23* rearrangements in thyroid lymphoma had a CDR3 sequence with shared amino acid motifs to those of thyroid …

    cambridge Repository record for Molecular Insights of Primary Thyroid B-cell Lymphomas by Somatic Genetic and Immunogenetic Profiling (opens in a new tab)

  9. Understanding the biology of CD180 in chronic lymphocytic leukemia

    … immunoglobulin heavy chain variable genes (IGHV), a subset of patients with a superior prognosis, which confirms previous observations. We also found that higher CD180 expression in both the peripheral blood and lymph nodes was associated with superior OS in CLL. Given the growing evidence …

    westminster Repository record for Understanding the biology of CD180 in chronic lymphocytic leukemia (opens in a new tab)

  10. Humanisierung von Maus-Hybridomantikörpern

    … eines flankierten NPTII Gens in den aktiven IGHV Genlokus wurde bereits erfolgreich in HEA125 getestet. Die homolog rekombinierten Zielzellen konnten mittels PCR nachgewiesen werden, waren aber nicht stabil. Deshalb ist die Einführung der spezifischen Rekombinationsstellen direkt mittels …

    heid-diss Repository record for Humanisierung von Maus-Hybridomantikörpern (opens in a new tab)

  11. Applications of next-generation technologies in the diagnosis of haematological diseases and cancer

    … the genome, including in patients with unmutated IgHV genes. Regions of localised hypermutation are present in CLL, with a number affecting genes associated with coding mutations in CLL, including ATM, KLHL6 and MEGF9. A number of mutation clusters are also identified in potentially regulatory …

    oxford-brookes Repository record for Applications of next-generation technologies in the diagnosis of haematological diseases and cancer (opens in a new tab)